Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 5/20 | 0.78 |
| ▸ | EGFR | P00533 | 4/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.69 |
| ▸ | INSR | P06213 | 6/20 | 0.69 |
| ▸ | IGF1R | P08069 | 4/20 | 0.68 |
| ▸ | ULK1 | O75385 | 1/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.67 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.67 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.67 |
| ▸ | CDC7 | O00311 | 1/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099910 | 0.94 | ZAP70 (0.75) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4099957 | 0.93 | ZAP70 (0.78) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4104330 | 0.92 | ZAP70 (0.79) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4089243 | 0.91 | ZAP70 (0.76) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4107018 | 0.91 | ZAP70 (0.76) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL12780216 | 0.90 | ZAP70 (0.78) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL12780145 | 0.89 | ZAP70 (0.85) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4088549 | 0.88 | ZAP70 (0.76) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4097618 | 0.88 | ZAP70 (0.76) | ZAP70EGFRLRRK2ALKINSR | |
| SCHEMBL4088556 | 0.88 | ZAP70 (0.76) | ZAP70EGFRLRRK2ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ZAP70 1678/4885EGFR 3112/4885LRRK2 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.